{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:42:53Z","timestamp":1790473373172,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12325-020-01285-2","type":"journal-article","created":{"date-parts":[[2020,3,22]],"date-time":"2020-03-22T01:03:30Z","timestamp":1584839010000},"page":"1724-1736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Proportion of High-Risk\/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review"],"prefix":"10.1007","volume":"37","author":[{"given":"Eric","family":"Bruckert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus Georg","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ramon","family":"Gonzalez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Giovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,21]]},"reference":[{"key":"1285_CR1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999\u20133058.","journal-title":"Eur Heart J"},{"key":"1285_CR2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"1285_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)62027-3","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390.","journal-title":"Lancet"},{"key":"1285_CR4","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"1285_CR5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"\u017d Reiner","year":"2011","unstructured":"Reiner \u017d, Catapano AL, De Backer G, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"key":"1285_CR6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1285_CR7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.atherosclerosis.2012.06.052","volume":"224","author":"RD Santos","year":"2012","unstructured":"Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis. 2012;224:150\u20133.","journal-title":"Atherosclerosis"},{"key":"1285_CR8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"R Conroy","year":"2003","unstructured":"Conroy R, Py\u00f6r\u00e4l\u00e4 K, Fitzgerald A, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987\u20131003.","journal-title":"Eur Heart J"},{"key":"1285_CR9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008\u201312.","journal-title":"JAMA"},{"key":"1285_CR10","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"1285_CR11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-146-8-200704170-00019","volume":"146","author":"U Ravnskov","year":"2007","unstructured":"Ravnskov U. Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets. Ann Intern Med. 2007;146:614 (author reply 614).","journal-title":"Ann Intern Med"},{"key":"1285_CR12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78:684\u201398.","journal-title":"Br J Clin Pharmacol"},{"key":"1285_CR13","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"1285_CR14","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1093\/eurheartj\/ehn478","volume":"29","author":"RH Mehta","year":"2008","unstructured":"Mehta RH, Bhatt DL, Steg PG, et al. Modifiable risk factors control and its relationship with 1\u00a0year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J. 2008;29:3052\u201360.","journal-title":"Eur Heart J"},{"key":"1285_CR15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/2047487312444995","volume":"20","author":"O Vedin","year":"2013","unstructured":"Vedin O, Hagstr\u00f6m E, Stewart R, et al. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol. 2013;20:678\u201385.","journal-title":"Eur J Prev Cardiol"},{"key":"1285_CR16","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","volume":"378","author":"S Yusuf","year":"2011","unstructured":"Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231\u201343.","journal-title":"Lancet"},{"key":"1285_CR17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","volume":"23","author":"K Kotseva","year":"2016","unstructured":"Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636\u201348.","journal-title":"Eur J Prev Cardiol"},{"key":"1285_CR18","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.jacc.2014.08.041","volume":"64","author":"TM Maddox","year":"2014","unstructured":"Maddox TM, Borden WB, Tang F, et al. Implications of the 2013 ACC\/AHA cholesterol guidelines for adults in contemporary cardiovascular practice. J Am Coll Cardiol. 2014;64:2183\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR19","doi-asserted-by":"crossref","first-page":"e001709","DOI":"10.1161\/JAHA.114.001709","volume":"4","author":"NS Shah","year":"2015","unstructured":"Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in myocardial infarction secondary prevention: the National Health and Nutrition Examination Surveys (NHANES), 1999\u20132012. J Am Heart Assoc. 2015;4:e001709.","journal-title":"J Am Heart Assoc"},{"key":"1285_CR20","doi-asserted-by":"crossref","first-page":"e013255","DOI":"10.1136\/bmjopen-2016-013255","volume":"7","author":"DL Steen","year":"2017","unstructured":"Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open. 2017;7:e013255.","journal-title":"BMJ Open"},{"key":"1285_CR21","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s12325-015-0252-y","volume":"32","author":"A de la Sierra","year":"2015","unstructured":"de la Sierra A, Pint\u00f3 X, Guijarro C, et al. Prevalence, treatment, and control of hypercholesterolemia in high cardiovascular risk patients: evidences from a systematic literature review in Spain. Adv Ther. 2015;32:944\u201361.","journal-title":"Adv Ther"},{"key":"1285_CR22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","volume":"8","author":"PP Toth","year":"2014","unstructured":"Toth PP, Foody JM, Tomassini JE, et al. Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J Clin Lipidol. 2014;8:107\u201316.","journal-title":"J Clin Lipidol"},{"key":"1285_CR23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacl.2013.06.002","volume":"7","author":"RJ Simpson","year":"2013","unstructured":"Simpson RJ, Tunceli K, Ramey DR, et al. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. J Clin Lipidol. 2013;7:399\u2013407.","journal-title":"J Clin Lipidol"},{"key":"1285_CR24","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","volume":"62","author":"SV Arnold","year":"2013","unstructured":"Arnold SV, Spertus JA, Masoudi FA, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62:1791\u2013801.","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/CIRCULATIONAHA.113.003589","volume":"129","author":"SV Arnold","year":"2014","unstructured":"Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation. 2014;129:1303\u20139.","journal-title":"Circulation"},{"issue":"418\u2013424","key":"1285_CR26","first-page":"e3","volume":"161","author":"U Javed","year":"2011","unstructured":"Javed U, Deedwania PC, Bhatt DL, et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2011;161(418\u2013424):e3.","journal-title":"Am Heart J"},{"key":"1285_CR27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med"},{"key":"1285_CR28","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med"},{"key":"1285_CR29","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"1285_CR30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"2017","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;2017:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1285_CR31","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"HPS3\/TIMI55\u2013REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217\u201327.","journal-title":"N Engl J Med"},{"key":"1285_CR32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"1285_CR33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.","journal-title":"BMJ"},{"key":"1285_CR34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/2047487314525531","volume":"21","author":"JA Finegold","year":"2014","unstructured":"Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21:464\u201374.","journal-title":"Eur J Prev Cardiol"},{"key":"1285_CR35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/ATVBAHA.116.306887","volume":"36","author":"JG Robinson","year":"2016","unstructured":"Robinson JG, Ray K. Counterpoint: low-density lipoprotein cholesterol targets are not needed in lipid treatment guidelines. Arterioscler Thromb Vasc Biol. 2016;36:586\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1285_CR36","doi-asserted-by":"crossref","unstructured":"Landmesser U, Chapman MJ, Stock JK, et al. 2017 update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39:1131\u201343.","DOI":"10.1093\/eurheartj\/ehx549"},{"key":"1285_CR37","doi-asserted-by":"crossref","unstructured":"Zamora A, Masana L, Comas-Cufi M, et al. N\u00famero de pacientes candidatos a recibir inhibidores de la PCSK9 seg\u00fan datos de 2,5 millones de participantes de la pr\u00e1ctica cl\u00ednica real. Revista Espa\u00f1ola de Cardiolog\u00eda. 2018;71:1010\u201317.","DOI":"10.1016\/j.recesp.2017.11.006"},{"key":"1285_CR38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","volume":"155","author":"PM Ho","year":"2008","unstructured":"Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772\u20139.","journal-title":"Am Heart J"},{"key":"1285_CR39","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.clinthera.2009.10.002","volume":"31","author":"Y Yang","year":"2009","unstructured":"Yang Y, Thumula V, Pace PF, Banahan BF, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31:2178\u201388.","journal-title":"Clin Ther"},{"key":"1285_CR40","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1185\/03007990802203279","volume":"24","author":"JM Foody","year":"2008","unstructured":"Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin. 2008;24:1987\u20132000.","journal-title":"Curr Med Res Opin"},{"key":"1285_CR41","doi-asserted-by":"crossref","unstructured":"Guglielmi V, Bellia A, Pecchioli S, et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis. 2017;263:36\u201341.","DOI":"10.1016\/j.atherosclerosis.2017.05.018"},{"key":"1285_CR42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ehjci\/jet251","volume":"15","author":"R Puri","year":"2014","unstructured":"Puri R, Libby P, Nissen SE, et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014;15:380\u20138.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1285_CR43","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","volume":"113","author":"EP Navarese","year":"2014","unstructured":"Navarese EP, Kowalewski M, Andreotti F, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113:1753\u201364.","journal-title":"Am J Cardiol"},{"key":"1285_CR44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","volume":"37","author":"SF Nielsen","year":"2015","unstructured":"Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2015;37:908\u201316.","journal-title":"Eur Heart J"},{"key":"1285_CR45","doi-asserted-by":"crossref","first-page":"i3283","DOI":"10.1136\/bmj.i3283","volume":"353","author":"A Matthews","year":"2016","unstructured":"Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283.","journal-title":"BMJ"},{"key":"1285_CR46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M16-0838","volume":"167","author":"H Zhang","year":"2017","unstructured":"Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167:221\u20137.","journal-title":"Ann Intern Med"},{"key":"1285_CR47","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"M-C Serban","year":"2017","unstructured":"Serban M-C, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"1285_CR48","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1185\/03007995.2012.717919","volume":"28","author":"B Eber","year":"2012","unstructured":"Eber B, Lautsch D, Fauer C, et al. Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. Curr Med Res Opin. 2012;28:1447\u201354.","journal-title":"Curr Med Res Opin"},{"key":"1285_CR49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1185\/03007995.2014.982751","volume":"31","author":"F Barkas","year":"2015","unstructured":"Barkas F, Milionis H, Kostapanos MS, Mikhailidis DP, Elisaf M, Liberopoulos E. How effective are the ESC\/EAS and 2013 ACC\/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin. 2015;31:221\u20138.","journal-title":"Curr Med Res Opin"},{"key":"1285_CR50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2016.05.003","volume":"217","author":"D Alexopoulos","year":"2016","unstructured":"Alexopoulos D, Anastasiou-Nana M, Elisaf MS, et al. A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients\u2019 quality of life in Greece: the CHALLENGE study. Int J Cardiol. 2016;217:183\u20139.","journal-title":"Int J Cardiol"},{"key":"1285_CR51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","volume":"19","author":"AK Gitt","year":"2012","unstructured":"Gitt AK, Drexel H, Feely J, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19:221\u201330.","journal-title":"Eur J Prev Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01285-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T12:25:19Z","timestamp":1666182319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01285-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,21]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01285-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,21]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}